Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry. uri icon

Overview

authors

publication date

  • August 1, 2024

Research

keywords

  • COVID-19
  • COVID-19 Drug Treatment
  • Dexamethasone
  • Hematologic Neoplasms
  • Registries
  • SARS-CoV-2

Identity

PubMed Central ID

  • PMC11290529

Scopus Document Identifier

  • 85200423425

Digital Object Identifier (DOI)

  • 10.3324/haematol.2023.284678

PubMed ID

  • 38572549

Additional Document Info

volume

  • 109

issue

  • 8